A stop-to-flare strategy that triggers immune control of hepatitis B virus (HBV) after discontinuation of nucleot(s)ide analogues (NAs) may work in carefully selected patients without cirrhosis or advanced fibrosis if the patients are closely monitored afterwards.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Hepatology - Malaysia digital copy today!
Treatment with nidufexor led to significantly reduced serum alanine aminotransferase (ALT) levels and hepatic fat fraction in patients with nonalcoholic steatohepatitis (NASH), according to a phase II study presented at ILC 2020.
A trivalent vaccine against hepatitis (hep B) is safe and effectively elicits robust immune response compared with a monovalent Hep B vaccine, according to the PROTECT and CONSTANT studies presented during the 2020 digital ILC.